Skip to content
Friday 14 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Monday 03 August 2015 5:10 pm

GSK rehires woman investigated for whistleblowing about bribery

By: Sarah Spickernell

Add as a preferred source on Google

Vivian Shi, the former Chinese GSK employee who was investigated for leaking information about bribery by the company, has been rehired. 
 
Read more: Glaxosmithkline China dismisses more than 100 over bribery scandal that cost company £300m
 
“We can confirm we have rehired Vivian,” the pharmaceutical company said in an e-mailed statement today. “We are not going to comment further on an individual employee.”
 
Last year, the Chinese arm of GSK was found guilty of bribing doctors and had to pay a fine of £297m. The authorities were first alerted to the illegal activity by a series of leaked emails and videos, and soon afterwards enquiries were launched by the UK Serious Fraud Office and US justice department. 
 
In 2013 Ms Shi became the focus of an internal investigation into who the culprit was, soon after she was fired in 2012 from her position as head of government affairs in China.
 
It was never proven that she was responsible for the leak, however, and she denied any involvement in a campaign against the company. 
 
It is not known whether she will be appointed to her original role or to a new one. When she was fired three years ago, GSK said it was on the grounds of alleged irregularities in travel expenses.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Markets & Economics

Categories

  • Markets

Related Topics

  • Company
  • GSK

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • Grandparents fund university degrees to avoid inheritance tax net

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • It’s not just Jason Arday, most of sociology is a scam

More from Morning Wire

  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

    Business Wire
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

    Business Wire
  • CoStar Data Shows Strong Prelet Activity Driving UK Lab Space Demand to a Record High

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook